Epidemiology Study - Overview

Age-Related Macular Degeneration (AMD) Study Objective:

To determine the prevalence and incidence of Age-Related Macular Degeneration (AMD) among individuals in a defined population. This objective outlines the primary aim of the study, which is to establish the frequency of Age-Related Macular Degeneration (AMD) within a specific age group and geographic area, while also seeking to understand potential factors contributing to its development. Moreover, the report is having geographic coverage including North America, Europe and rest of the world however customisation can be made in the geographic coverage.

Age-Related Macular Degeneration (AMD) Study USP:

• This epidemiological study on Age-Related Macular Degeneration (AMD) stands out due to its comprehensive approach in establishing precise prevalence rates, identifying novel risk factors, and exploring geographical variations in a diverse population.

• By integrating advanced imaging techniques with robust statistical analyses, the study aims to provide actionable insights to identify treatment opportunities, target population, and an overview on public health initiatives aimed at mitigating the impact of Age-Related Macular Degeneration (AMD) related health problems.

• Through meticulous data collection and rigorous methodology, the study not only contributes to the scientific understanding of cardiovascular diseases but also serves as a foundation for future research events and healthcare policymaking in addressing this increasing Age-Related Macular Degeneration (AMD) cases.

Age-Related Macular Degeneration (AMD) related Study Overview:

The study Defines Age-Related Macular Degeneration (AMD) as an advanced form of disease. The significance of studying Age-Related Macular Degeneration (AMD) epidemiology is due to its increasing prevalence in different age populations.

Age-Related Macular Degeneration (AMD) Study Design:

Population: The target population and the sampling method (e.g., random sampling from healthcare registries or population databases)

Data Collection: Detail methods for identifying Age-Related Macular Degeneration (AMD) cases (e.g., clinical examination, imaging studies) and demographic data (age, sex, ethnicity).

Age-Related Macular Degeneration (AMD) Epidemiological Parameters:

Prevalence: Prevalence rates considered per 1,000 or 10,000 population.

Incidence: Determine annual incidence rates per 1,000 person-years.

Risk Factors: Analyse associations between Age-Related Macular Degeneration (AMD) and potential risk factors (e.g., age, smoking, genetics).

Geographical Variations: Compare prevalence or incidence rates across different regions or countries.

Age-Related Macular Degeneration (AMD) study summary:

Age-Related Macular Degeneration (AMD) study summarizes the prevalence, incidence, possible risk factors, and geographic variations of the Age-Related Macular Degeneration (AMD) worldwide.

Age-Related Macular Degeneration (AMD) Disease overview:

Age-related macular degeneration (AMD) is a progressive eye disease, affecting macula, central part of retina responsible for sharp and detailed vision, causing central vision loss.

It is also classified into early AMD, which is initial stage of AMD, often asymptomatic with mild vision changes and early AMD, which is further segmented into Dry AMD caused due to gradual thinning of macula dur to accumulation of drusen( yellow deposits under retina) leading to death of retinal cells and wet AMD, caused due to abnormal blood vessels grow beneath macula leaking fluid leading to rapid retinal damage.

AMD is the third leading cause of blindness globally, few estimations state that by 2040, 288 million individuals will be suffering with this disease, which represents 50% increase from the cases in the year 2020.

There are several medicines available in the market for the treatment of Age-Related Macular Degeneration (AMD), the key market players manufacturing this therapeutics are as follows; Santen Pharmaceuticals Inc. (Japan), Allergan plc (Ireland)c, Bausch Health (Canada), Alimera Science Inc. (US), Phio Pharmaceuticals Corp (US), Ocumension Therapeutics Co. Ltd (China), Belite Bio Inc. (US), Kubota Vision Inc. (US), Iveric Bio (US), Eyestem Research Pvt Ltd (India).

Age-Related Macular Degeneration (AMD) Demographic and Environmental Risk Factors:

Age and Sex: Age-related macular degeneration (AMD) affects one in eight people 60 years of age or older and is the most common cause of irreversible blindness in older persons in developed countries. Prevalence of AMD increases significantly with age. In US approximately 12.6 % of individuals aged 40 and older are affected, 2% among age 40 to 44% to prevalence rising 46.6% among those aged 85 and older. According to one of the studies published in PubMed Central in US early-stage AMD affects approximately 10.73% of females and 12.72% of males aged 40 and older. Furthermore, prevalence of late-stage AMD is similar between both genders with rates 0.94% fir females and 0.95% for males in same age group.

Ethnicity: AMD prevalence varies greatly by ethnicity, with non-Hispanic White Europeans carrying the majority of the disease burden. there is still a significant chronic burden among Hispanics (10.4%), Africans (7.5%), and Asians (7.4%). Even yet, other researchers have estimated a lower disease burden in the United States, with non-Hispanic White Europeans having the highest frequency at about 7.3%

Risk Factors causing Age-Related Macular Degeneration (AMD): Advancing age is the major risk factor for causing Age-Related Macular Degeneration (AMD), smoking is considered as strong modifiable risk factor for this disease, family history of AMD can increase chances of getting this disease, high plasma high density lipoprotein (HDL) cholesterol levels are also associated with increased risk of early AMD.

Age-Related Macular Degeneration (AMD) Market Scope:

Drivers: Growing Prevalence of Age-Related Macular Degeneration with growing geriatric population to boost the market growth.

Despite an increasing life expectancy and decreasing fertility levels, the older population in the world is growing rapidly, according to a UN report published in December 2020. In 2020, 727 million people were 65 or older, and the number is predicted to rise to 1.5 billion by 2050, according to the same report. There is a projected increase in the proportion of people aged 65 and over in the population from 9.3% in 2020 to 16.0% in 2050. The same is predicted in China. The UN projects a rise in the share of seniors from 12% in 2020 to 26% by 2050.

To support national and international health goals, comprehensive and comparable health spending estimates are crucial to health policy and planning. On February 20, 2019, the World Health Organization (WHO) released a new report on health expenditure, indicating that health spending increased by 6% in low- and middle-income countries and 4% in high-income countries. There is a shift in how external and domestic funding is used, but in middle-income countries, external funding is declining. Governments spend less than 40% on primary health care.

Only a few medications, primarily anti-VEGFs, are approved to treat age-related macular degeneration. Anti-VEGF drugs require repeated and inconvenient intraocular injections, which makes treatment more burdensome and results in non-adherence. It is being developed by companies to develop longer-acting anti-VEGFs and vitreous implants to facilitate sustained drug delivery to overcome this obstacle. It is expected that long-acting anti-VEGF drugs such as Beovu and Vabysmo will propel market growth in the coming years. Still, the entry of biosimilars and a high adoption rate of off-label drugs like impede market growth. 

However, the FDA approved a biosimilar version under the brand name BYOOVIZ in September 2021 for treating wet AMD, myopic choroidal neovascularization, and retinal vein occlusion in the United States. This is another factor driving the growth of the dry age-related macular degeneration market revenue.

Restraints: high treatment cost, limited treatment options available in the market, lack of awareness and early diagnosis of disease and risk of side effects and complications are the major factors which can hamper the growth of global Age-Related Macular Degeneration (AMD) market.